Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases

Diversity of the Human Intestinal Microbial Flora

Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913 · see citing works

Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease

The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · see citing works

The Treatment-Naive Microbiome in New-Onset Crohn’s Disease

Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220 · see citing works

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

Kornbluth, A. A., & Sachar, D. B. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,019 · see citing works

The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead

Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789 · see citing works

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

Sartor, R. B. (2006) · Nature Clinical Practice Gastroenterology &#38 Hepatology · doi:10.1038/ncpgasthep0528 · Cited by 1,763 · see citing works

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

Dignass, A. U., Assche, G. V., Lindsay, J. O., Lémann, M., Söderholm, J. D., Colombel, J., Danese, S., D’Hoore, A., Gassull, M. À., Gomollón, F., et al. (2010) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,491 · see citing works

Management of Crohn's Disease in Adults

Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,184 · see citing works

Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases

Frank, D. N., Robertson, C. E., Hamm, C. M., Kpadeh, Z. Z., Zhang, T., Chen, H., Zhu, W., Sartor, R. B., Boedeker, E. C., Harpaz, N., et al. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21339 · Cited by 594 · see citing works

Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis

Khan, K. J., Ullman, T. A., Ford, A. C., Abreu, M. T., Abadir, A., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.72 · Cited by 569 · see citing works

European evidence-based Consensus on the management of ulcerative colitis: Current management

Travis, S. P. L., Stange, E. F., Lémann, M., Öresland, T., Bemelman, W. A., Chowers, Y., Colombel, J. F., D’Haens, G., Ghosh, S. K., Marteau, P. R., et al. (2008) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2007.11.002 · Cited by 558 · see citing works

Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature

Haberman, Y., Tickle, T. L., Dexheimer, P. J., Kim, M., Tang, D., Karns, R. A., Baldassano, R. N., Noe, J. D., Rosh, J. R., Markowitz, J. F., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75436 · Cited by 523 · see citing works

Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome

Knights, D., Lassen, K. G., & Xavier, R. J. (2013) · Gut · doi:10.1136/gutjnl-2012-303954 · Cited by 468 · see citing works

Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population

Kappelman, M. D., Moore, K. R., Allen, J. K., & Cook, S. F. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2371-5 · Cited by 452 · see citing works

Complex host genetics influence the microbiome in inflammatory bowel disease

Knights, D., Silverberg, M. S., Weersma, R. K., Gevers, D., Dijkstra, G., Huang, H., Tyler, A. D., van Sommeren, S., Imhann, F., Stempak, J. M., et al. (2014) · Genome Medicine · doi:10.1186/s13073-014-0107-1 · Cited by 418 · see citing works

Mutual repression between steroid and xenobiotic receptor and NF- B signaling pathways links xenobiotic metabolism and inflammation

Zhou, C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26283 · Cited by 401 · see citing works

Bacterial translocation: Overview of mechanisms and clinical impact

Balzan, S. M. P., Quadros, C. A., de Cleva, R., Zilberstein, B., & Cecconello, I. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04933.x · Cited by 370 · see citing works

Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes

Langmann, T., Moehle, C., Mauerer, R., Scharl, M. M., Liebisch, G., Zahn, A., Stremmel, W., & Schmitz, G. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.019 · Cited by 335 · see citing works

Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis

Schwab, M. G., Schaeffeler, E., Marx, C., Fromm, M. F., Kaskas, B., Metzler, J., Stange, E. F., Herfarth, H. H., Schöelmerich, J., Gregor, M., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50010 · Cited by 323 · see citing works

Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases

Packey, C. D., & Sartor, R. B. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32832a8a5d · Cited by 319 · see citing works

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)

Dewint, P., Hansen, B. E., Verhey, E., Oldenburg, B., Hommes, D. W., Pierik, M. J., Ponsioen, C. Y., van Dullemen, H. M., Rüssel, M. G., Bodegraven, A. A. V., et al. (2013) · Gut · doi:10.1136/gutjnl-2013-304488 · Cited by 263 · see citing works

Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential

Scarpignato, C., & Pelosini, I. (2005) · Chemotherapy · doi:10.1159/000081990 · Cited by 242 · see citing works

Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-κB target gene expression

Shah, Y. M., Ma, X., Morimura, K., Kim, I., & Gonzalez, F. J. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00528.2006 · Cited by 231 · see citing works

The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications

Goldsmith, J. R., & Sartor, R. B. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0953-z · Cited by 213 · see citing works

National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States

Nguyen, G. C., Chong, C. A. K. Y., & Chong, R. Y. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.09.001 · Cited by 196 · see citing works

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system

Maccaferri, S., Vitali, B., Klinder, A., Kolida, S., Ndagijimana, M., Laghi, L., Calanni, F., Brigidi, P., Gibson, G. R., & Costabile, A. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq345 · Cited by 186 · see citing works

Genetics and Environmental Interactions Shape the Intestinal Microbiome to Promote Inflammatory Bowel Disease Versus Mucosal Homeostasis

Sartor, R. B. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.10.036 · Cited by 178 · see citing works

The role of mucosal immunity and host genetics in defining intestinal commensal bacteria

Hansen, J. J., Gulati, A., & Sartor, R. B. (2010) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32833f1195 · Cited by 177 · see citing works

Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease

Prantera, C., Lochs, H. H., Grimaldi, M., Danese, S., Scribano, M. L., & Gionchetti, P. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.11.032 · Cited by 174 · see citing works

Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation

Cheng, J., Shah, Y. M., Ma, X., Pang, X., Tanaka, T., Kodama, T., Krausz, K. W., & Gonzalez, F. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.170225 · Cited by 162 · see citing works

PXR: A Xenobiotic Receptor of Diverse Function Implicated in Pharmacogenetics

Zhang, B., Xie, W., & Krasowski, M. D. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1695 · Cited by 160 · see citing works

Pregnane X receptor as a target for treatment of inflammatory bowel disorders

Cheng, J., Shah, Y. M., & Gonzalez, F. J. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.003 · Cited by 159 · see citing works

Acute and chronic pouchitis—pathogenesis, diagnosis and treatment

Shen, B. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.58 · Cited by 152 · see citing works

Letter to the Editor

Gionchetti, P., Rizzello, F., Ferrieri, A., Venturi, A., Brignola, C., Ferretti, M., Peruzzo, S., Miglioli, M., & Campieri, M. (1999) · Digestive Diseases and Sciences · doi:10.1023/a:1026648812439 · Cited by 150 · see citing works

Newly Developed Antibiotic Combination Therapy for Ulcerative Colitis: A Double-Blind Placebo-Controlled Multicenter Trial

Ohkusa, T., Kato, K., Terao, S., Chiba, T., Mabe, K., Murakami, K., Mizokami, Y., Sugiyama, T., Yanaka, A., Takeuchi, Y., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.84 · Cited by 138 · see citing works

Rifaximin Is a Gut-Specific Human Pregnane X Receptor Activator

Ma, X., Shah, Y. M., Guo, G. L., Wang, T., Krausz, K. W., Idle, J. R., & Gonzalez, F. J. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121913 · Cited by 127 · see citing works

Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease

Wang, S., Wang, Z., & Yang, C. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.718 · Cited by 126 · see citing works

Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells

Mencarelli, A., Renga, B., Palladino, G., D’Amore, C., Ricci, P., Distrutti, E., Barbanti, M., Baldelli, F., & Fiorucci, S. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.06.058 · Cited by 120 · see citing works

Rifaximin: beyond the traditional antibiotic activity

Calanni, F., Renzulli, C., Barbanti, M., & Viscomi, G. C. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.106 · Cited by 119 · see citing works

Experimental and Clinical Pharmacology of Rifaximin, a Gastrointestinal Selective Antibiotic

Scarpignato, C., & Pelosini, I. (2006) · Digestion · doi:10.1159/000089776 · Cited by 112 · see citing works

Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches

Hansen, J. J., & Sartor, R. B. (2015) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-014-0042-7 · Cited by 104 · see citing works

Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells

Mencarelli, A., Migliorati, M., Barbanti, M., Cipriani, S., Palladino, G., Distrutti, E., Renga, B., & Fiorucci, S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.022 · Cited by 103 · see citing works

Inhibition of Intestinal Bacterial Translocation with Rifaximin Modulates Lamina propria Monocytic Cells Reactivity and Protects against Inflammation in a Rodent Model of Colitis

Fiorucci, S., Distrutti, E., Mencarelli, A., Barbanti, M., Palazzini, E., & Morelli, A. (2002) · Digestion · doi:10.1159/000068362 · Cited by 98 · see citing works

Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles

Brown, E. L., Xue, Q., Jiang, Z., Xu, Y., & DuPont, H. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00691-09 · Cited by 96 · see citing works

Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: A preliminary report

Turner, D., Levine, A., Kolho, K., Shaoul, R. R., & Ledder, O. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.05.010 · Cited by 92 · see citing works

Effects of Rifaximin Administration on the Intestinal Microbiota in Patients with Ulcerative Colitis

Brigidi, P., Swennen, E., Rizzello, F., Bozzolasco, M., & Matteuzzi, D. (2002) · Journal of Chemotherapy · doi:10.1179/joc.2002.14.3.290 · Cited by 88 · see citing works

From genetics of inflammatory bowel disease towards mechanistic insights

Graham, D. B., & Xavier, R. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.04.001 · Cited by 86 · see citing works

Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis

Terc, J. D., Hansen, A., Alston, L. A., & Hirota, S. A. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.01.007 · Cited by 86 · see citing works

The mdr1a–/– Mouse Model of Spontaneous Colitis: A Relevant and Appropriate Animal Model to Study Inflammatory Bowel Disease

Wilk, J. N., Bilsborough, J., & Viney, J. L. (2005) · Immunologic Research · doi:10.1385/ir:31:2:151 · Cited by 83 · see citing works

Multidrug Resistance Is Common in Escherichia coli Associated with Ileal Crohnʼs Disease

Dogan, B., Scherl, E., Bosworth, B. P., Yantiss, R. K., Altier, C., McDonough, P. L., Jiang, Z., DuPont, H. L., Garneau, P., Harel, J., et al. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22971 · Cited by 80 · see citing works

Xenobiotic receptor meets NF-κB, a collision in the small bowel

Xie, W., & Tian, Y. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.08.004 · Cited by 68 · see citing works

Drosophila as a model for intestinal dysbiosis and chronic inflammatory diseases

Lee, K., & Lee, W. (2013) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2013.05.005 · Cited by 62 · see citing works

Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB , and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux Pumps

Kothary, V., Scherl, E., Bosworth, B. P., Jiang, Z., DuPont, H. L., Harel, J., Simpson, K. W., & Dogan, B. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02163-12 · Cited by 57 · see citing works

Bacterial Translocation in Patients With Crohn's Disease Undergoing Surgery

Takesue, Y., Ohge, H., Uemura, K., Imamura, Y., Murakami, Y., Yokoyama, T., Kakehashi, M., & Sueda, T. (2002) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-7256-z · Cited by 55 · see citing works

Adjunct antibiotic combination therapy for steroid‐refractory or ‐dependent ulcerative colitis: an open‐label multicentre study

Kato, K., Ohkusa, T., Terao, S., Chiba, T., Murakami, K., Yanaka, A., Uehara, T., Ishii, Y., Soma, M., & Tajiri, H. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12688 · Cited by 45 · see citing works

Pregnane X Receptor (PXR) at the Crossroads of Human Metabolism and Disease

Koutsounas, I. S., Theocharis, S. E., Patsouris, E., & Giaginis, C. (2013) · Current Drug Metabolism · doi:10.2174/1389200211314030009 · Cited by 44 · see citing works

Rifaximin for active ulcerative colitis

Guslandi, M., Petrone, M. C., & Testoni, P. A. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000215092.85116.6c · Cited by 44 · see citing works

Bile Acid Malabsorption Deactivates Pregnane X Receptor in Patients with Crohn’s Disease

Iwamoto, J., Saito, Y., Honda, A., Miyazaki, T., Ikegami, T., & Matsuzaki, Y. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f423 · Cited by 40 · see citing works

Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States

Long, M. D., Hutfless, S. M., Kappelman, M. D., Khalili, H., Kaplan, G. G., Bernstein, C. N., Colombel, J., Gower‐Rousseau, C., Herrinton, L. J., Velayos, F. S., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000435441.30107.8b · Cited by 40 · see citing works

The Intestinal Microbiota in Inflammatory Bowel Diseases

Sartor, R. B. (2014) · Nestlé Nutrition Institute Workshop series · doi:10.1159/000360674 · Cited by 39 · see citing works

Antibiotics, Probiotics and Prebiotics in IBD

Bernstein, C. N. (2014) · Nestlé Nutrition Institute Workshop series · doi:10.1159/000360713 · Cited by 36 · see citing works

Effect of Rifaximin on Intestinal Bacterial Overgrowth in Crohn's Disease as Assessed by the H2-Glucose Breath Test

Biancone, L., Vernia, P., Agostini, D., Ferrieri, A., & Pallone, F. (2000) · Current Medical Research and Opinion · doi:10.1185/0300799009117003 · Cited by 36 · see citing works

Use of antibiotics in the treatment of Crohn’s disease

Scribano, M. L. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i5.648 · Cited by 34 · see citing works

Is Rifaximin Effective in Maintaining Remission in Crohn's Disease?

Jigaranu, A. O., Nedelciuc, O., Blaj, A., Badea, M., Mihai, C., Diculescu, M., & Prelipcean, C. C. (2014) · Digestive Diseases · doi:10.1159/000358141 · Cited by 32 · see citing works

Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis

Schrodt, C. A., McHugh, E. E., Gawinowicz, M. A., DuPont, H. L., & Brown, E. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068550 · Cited by 21 · see citing works

The role of antimicrobials in Crohn’s disease

Kale-Pradhan, P. B., Zhao, J., Palmer, J. R., & Wilhelm, S. M. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.13.6 · Cited by 14 · see citing works

History of antimicrobial drug discovery: Major classes and health impact

Aminov, R. I. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.001 · Cited by 305 · see citing works

The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation

Amoroso, C., Perillo, F., Strati, F., Fantini, M. C., Caprioli, F., & Facciotti, F. (2020) · Cells · doi:10.3390/cells9051234 · Cited by 243 · see citing works

Targeting nuclear receptors for the treatment of fatty liver disease

Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.011 · Cited by 212 · see citing works

Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure

Trebicka, J., Bork, P., Krag, A. A., & Arumugam, M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00376-3 · Cited by 203 · see citing works

A Synthesis-Based Reverse Metabolomics Approach for the Discovery of Chemical Structures from Humans and Animals.

Dorrestein, P., Gentry, E., Collins, S., Panitchpakdi, M., Belda-Ferre, P., Stewart, A., Wang, M., Jarmusch, A., Avila-Pacheco, J., Plichta, D., et al. (2021) · doi:10.21203/rs.3.rs-820302/v1 · Cited by 197 · see citing works

A comprehensive review of the application of probiotics and postbiotics in oral health

Rad, A. H., Pourjafar, H., & Mirzakhani, E. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1120995 · Cited by 200 · see citing works

Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases

Oka, A., & Sartor, R. B. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06090-z · Cited by 185 · see citing works

Stress triggers flare of inflammatory bowel disease in children and adults

Sun, Y., Li, L., Xie, R., Wang, B., Jiang, K., & Cao, H. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00432 · Cited by 171 · see citing works

Gut Microbiota-Derived Propionate Regulates the Expression of Reg3 Mucosal Lectins and Ameliorates Experimental Colitis in Mice

Bajic, D., Niemann, A., Hillmer, A.-K., Mejías‐Luque, R., Bluemel, S., Docampo, M. D., Funk, M. C., Tonin, E., Boutros, M., Schnabl, B., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa065 · Cited by 112 · see citing works

pH and Reactive Oxygen Species‐Sequential Responsive Nano‐in‐Micro Composite for Targeted Therapy of Inflammatory Bowel Disease

Bertoni, S., Liu, Z., Correia, A., Martins, J. P., Rahikkala, A., Fontana, F., Kemell, M., Liu, D., Albertini, B., Passerini, N., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201806175 · Cited by 105 · see citing works

Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases

Mishima, Y., & Sartor, R. (2019) · Journal of gastroenterology · doi:10.1007/s00535-019-01618-1 · Cited by 86 · see citing works

Postbiotics, as Dynamic Biomolecules, and Their Promising Role in Promoting Food Safety

(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac116.1452914544 · Cited by 85 · see citing works

Antibiotics in IBD: Still a Role in the Biological Era?

Ledder, O., & Turner, D. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy067 · Cited by 81 · see citing works

Research progress on the relationship between intestinal microecology and intestinal bowel disease

Fu, Q.-H., Song, T., Ma, X., & Cui, J. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12262 · Cited by 74 · see citing works

Polyphenols and Intestinal Health

Martinez, K., Mackert, J. D., & McIntosh, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805376-8.00018-6 · Cited by 78 · see citing works

Bugging inflammation: role of the gut microbiota

Shen, S., & Wong, C. H. Y. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.12 · Cited by 66 · see citing works

Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting

Bertoni, S., Machness, A., Tiboni, M., Bártolo, R., & Santos, H. A. (2019) · Biopolymers · doi:10.1002/bip.23336 · Cited by 58 · see citing works

Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor

Bartolini, D., Franco, F., Torquato, P., Marinelli, R., Cerra, B., Ronchetti, R., Schön, A., Fallarino, F., LUCA, A. D., Bellezza, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00012 · Cited by 49 · see citing works

Plant-derived vesicle-like nanoparticles: A new tool for inflammatory bowel disease and colitis-associated cancer treatment

Fang, X., Feng, J., Zhu, X., Feng, D., & Zheng, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.021 · Cited by 46 · see citing works

Antibiotics in inflammatory bowel diseases: do we know what we’re doing?

Ledder, O. (2019) · Translational Pediatrics · doi:10.21037/tp.2018.11.02 · Cited by 45 · see citing works

P-glycoprotein multidrug transporter in inflammatory bowel diseases: More questions than answers

Cario, E. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i9.1513 · Cited by 39 · see citing works

The Intricate Link among Gut “Immunological Niche,” Microbiota, and Xenobiotics in Intestinal Pathology

Pagliari, D., Gambassi, G., Piccirillo, C. A., & Cianci, R. (2017) · Mediators of Inflammation · doi:10.1155/2017/8390595 · Cited by 37 · see citing works

Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome

Kane, J. S., & Ford, A. C. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1140571 · Cited by 35 · see citing works

New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases

Bajaj, J. S., Barbara, G., DuPont, H. L., Mearin, F., Gasbarrini, A., & Tack, J. F. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.04.020 · Cited by 32 · see citing works

Current Trends in Macrocyclic Drug Discovery and beyond -Ro5

Alihodžić, S., Bukvić, M., Elenkov, I., Hutinec, A., Koštrun, S., Pešić, D., Saxty, G., Tomašković, L., & Žiher, D. (2018) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2018.01.002 · Cited by 31 · see citing works

Microbiota-targeted therapies in inflammation resolution

Strati, F., Lattanzi, G., Amoroso, C., & Facciotti, F. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101599 · Cited by 30 · see citing works

The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease

Lopetuso, L. R., Napoli, M., Rizzatti, G., & Gasbarrini, A. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1483333 · Cited by 27 · see citing works

Probing gut‐brain links in Alzheimer's disease with rifaximin

Suhocki, P. V., Ronald, J., Diehl, A. M., Murdoch, D. M., & Doraiswamy, P. M. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12225 · Cited by 27 · see citing works

Inflammatory Bowel Diseases: The Role of Gut Microbiota

Musis, C. D., Granata, L., Dallio, M., Miranda, A., Gravina, A. G., & Romano, M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200420144128 · Cited by 27 · see citing works

Naringenin: A Promising Immunomodulator for Anti-inflammatory, Neuroprotective and Anti-cancer Applications

Solanki, S., Vig, H., Khatri, N., Singh, B. P., Khan, M. S., Devgun, M., Wal, P., & Wal, A. (2024) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/0118715230320007240708074939 · Cited by 21 · see citing works

Rifamycin SV exhibits strong anti-inflammatory in vitro activity through pregnane X receptor stimulation and NFκB inhibition

Rosette, C., Agan, F. J., Rosette, N., Moro, L., Mazzetti, A., Hassan, C., & Gerloni, M. (2019) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2019.01.002 · Cited by 21 · see citing works

‘Brain Fogginess’ and D-Lactic Acidosis: Probiotics Are Not the Cause

Quigley, E. M. M., Pot, B., & Sanders, M. E. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0057-9 · Cited by 19 · see citing works

Ligand flexibility and binding pocket malleability cooperate to allow selective PXR activation by analogs of a promiscuous nuclear receptor ligand

Huber, A. D., Poudel, S., Li, Y., Lin, W., Wu, J., Miller, D. J., & Chen, T. (2023) · Structure · doi:10.1016/j.str.2023.08.020 · Cited by 16 · see citing works

The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review

DuPont, H. L. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-23 · Cited by 15 · see citing works

Therapeutic efficacy of rifaximin loaded tamarind gum polysaccharide nanoparticles in TNBS induced IBD model Wistar rats

Amaldoss, M. J. N., Ahmed, I., Kumar, J., & Sharma, A. K. (2021) · Reports of Practical Oncology & Radiotherapy · doi:10.5603/rpor.a2021.0100 · Cited by 14 · see citing works

Design and Optimization of 1H-1,2,3-Triazole-4-carboxamides as Novel, Potent, and Selective Inverse Agonists and Antagonists of PXR

Li, Y., Lin, W., Chai, S. C., Wu, J., Annu, K., & Chen, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01640 · Cited by 13 · see citing works

P2X4 receptor modulates gut inflammation and favours microbial homeostasis in colitis

Zhong, P., Wu, H., Ma, Y., Xu, X., Jiang, Y., Jin, C., Zhu, Q., Liu, X., Suo, Z., & Wang, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1227 · Cited by 12 · see citing works

Bioinformatis analysis reveals possible molecular mechanism of PXR on regulating ulcerative colitis

Guo, H., Yan, C., & Chi, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-83742-8 · Cited by 10 · see citing works

Learning from the research on amebiasis and gut microbiome: Is stimulation by gut flora essential for effective neutrophil mediated protection from external pathogens?

Watanabe, K., & Petri, W. A. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1479626 · Cited by 10 · see citing works

Effect of Shenling Baizhu San on Intestinal Flora in a Rat Model of Ulcerative Colitis with Spleen Deficiency and Dampness

Luo, Y., Zhu, F., Wu, J., Wu, J., Wu, P., & Liu, Y. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/9985147 · Cited by 9 · see citing works

Modulation of intestinal immune cell responses by eubiotic or dysbiotic microbiota in inflammatory bowel diseases

Facciotti, F. (2022) · PharmaNutrition · doi:10.1016/j.phanu.2022.100303 · Cited by 8 · see citing works

Effects of Vitamin D3 on Intestinal Flora in a Mouse Model of Inflammatory Bowel Disease Treated with Rifaximin

Gu, Z., Duan, M., Sun, Y., Leng, T., Xu, T., Gu, Y., Gu, Z., Lin, Z., Yang, L., & Ji, M. (2020) · Medical Science Monitor · doi:10.12659/msm.925068 · Cited by 8 · see citing works

Microbiome–Gut–Brain Axis: Implications for the Links Between Inflammatory Bowel Disease and Neuropsychiatric Disorders

Tian, C., Yang, M., Chen, K., Luo, D., Yue, N.-N., Zhao, H., Zhang, Y., Lu, J., Liang, Y.-J., Song, Y., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s514838 · Cited by 7 · see citing works

Effects of Rifaximin on Luminal and Wall-Adhered Gut Commensal Microbiota in Mice

Ferrer, M., Aguilera, M., & Martı́nez, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020500 · Cited by 7 · see citing works

Treatment Perspectives in Crohn’s Disease

Vetter, M., & Neurath, M. F. (2018) · Digestion · doi:10.1159/000488449 · Cited by 6 · see citing works

In Vitro Safety Signals for Potential Clinical Development of the Anti-Inflammatory Pregnane X Receptor Agonist FKK6

Dvořák, Z., Vyhlídalová, B., Pečinková, P., Li, H., Anzenbacher, P., Špičáková, A., Anzenbacherová, E., Chow, V., Liu, J.-B., Krause, H. M., et al. (2023) · bioRxiv · doi:10.1016/j.bioorg.2024.107137 · Cited by 7 · see citing works

The Effects of Rifampin, Povidone-Iodine and Hydrogen Peroxide on the Formation of Epidural Fibrosis in the Experimental Epidural Fibrosis Model

Kızılay, Z., Çetin, N. K., İsmailoğlu, Ö., Yılmaz, A., Ömürlü, İ. K., Coşkun, M. E., & Aktaş, S. (2016) · Inflammation · doi:10.1007/s10753-016-0383-6 · Cited by 6 · see citing works

Pathogens in Crohn's Disease: The Role of Adherent Invasive Escherichia coli

Iaquinto, G., Aufiero, V. R., Mazzarella, G., Lucariello, A., Panico, L., Melina, R., Iaquinto, S., Luca, A. D., & Sellitto, C. (2023) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2023050088 · Cited by 4 · see citing works

Citrobacter rodentium infection inhibits colonic P-glycoprotein expression

Patel, M., Kumar, A., Jayawardena, D., Priyamvada, S., Anbazhagan, A. N., Alrefai, W. A., Gill, R. K., Dudeja, P. K., & Saksena, S. (2019) · Gene Reports · doi:10.1016/j.genrep.2019.100549 · Cited by 4 · see citing works

Effect of topical rifamycin application on epidural fibrosis in rats

Dinç, C. (2019) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2019.2442 · Cited by 3 · see citing works

Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use

Nathwani, R., Mullish, B. H., Koeckerling, D., Cole, A., Selvapatt, N., & Dhar, A. (2021) · European Medical Journal · doi:10.33590/emj/21-00026 · Cited by 2 · see citing works

Rifaximin Inhibits Small Bowel Angiodysplasia-Associated Angiogenesis by Attenuating LncRNA-HIF1A-AS2/miR-153-3p/HIF-1 α/Ang-2 Axis

Peng, S., Yin, A., Liao, F., & Zhao, L. (2025) · Current Medical Science · doi:10.1007/s11596-025-00061-z · Cited by 1 · see citing works

Gut Microbiome and Gastrointestinal Disorders

Legaki, E., Karanasou, E. A., & Gazouli, M. (2021) · The microbiomes of humans, animals, plants, and the environment · doi:10.1007/978-3-030-59642-2_3 · Cited by 1 · see citing works

INTESTINAL DYSBIOSIS IN COVID-19Preprint

Bozkurt, H. S. (2020) · doi:10.31219/osf.io/fsr3h · Cited by 1 · see citing works

BactDNA as an Independent Risk Factor for Short-Term Crohn’s Disease Recurrence

Sartini, A., Verga, M. C., Marzi, L., Maria, N. D., & Villa, E. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.333

Rifaximin induces and maintains clinical remission in a dachshund with chronic enteropathy: antibiotic‐responsive diarrhoea or inflammatory bowel disease?

Menozzi, A., Dall’Aglio, M., Quintavalla, F., Meucci, V., & Bertini, S. (2017) · Veterinary Record Case Reports · doi:10.1136/vetreccr-2016-000423

Rifaximin for the treatment of Crohn’s disease

Tsai, H. H. (2020) · GastroHep · doi:10.1002/ygh2.423

Gut Microbiota and Inflammatory Bowel Diseases

Jacob, A., & Mathew, J. (2023) · doi:10.1002/9781119904786.ch10

Redox nanoparticles in colon drug targeting

Vo, N. P., Ho, A., & Ho, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24806-1.00017-0

Role of the gut microbiome in the pathogenesis of inflammatory bowel disease

Banerjee, S., Adhikary, P., De, D., Kalam, A., Chowdhury, S., & Mal, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40483-2.00021-2

BindingDB Entry 50009336: Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor.

BindingDB (2021) · UC San Diego · doi:10.7270/q23r0x9b

BindingDB Entry 50018581: Design and Optimization of 1

BindingDB (2024) · UC San Diego · doi:10.7270/q2qn6c1z

Rifaximin in the treatment of inflammatory bowel disease

Guslandi, M. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i42.4643 · Cited by 50 · see citing works

EFFECT OF PREGNANE XENOBIOTIC RECEPTOR ACTIVATION ON INFLAMMATORY BOWEL DISEASE TREATED WITH RIFAXIMIN.

Wan, Y. C., LI, T. W., Yd, H., Hy, Z., Lin, H., & Zhang, B. (2015) · PubMed · Cited by 12 · see citing works

Research progress of rifaximin in the treatment of inflammatory bowel disease

Guo, C. (2013) · Chinese Journal of Gastroenterology and Hepatology

The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease

Lopetuso, L. R., Napoli, M., Rizzatti, G., & Gasbarrini, A. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1483333 · Cited by 27 · see citing works

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system--authors' response

Maccaferri, S., Vitali, B., Klinder, A., Brigidi, P., & Costabile, A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr080